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The cloning of antithrombin III (AT1111 comple- 
mentary deoxyribonucleic acids and the determi- 
nation of the AT111 gene structure have permit- 
ted a systematic evaluation of the molecular 
basis for inherited AT111 deficiencies. Sixteen 
kindreds with the most common form of the defi- 
ciency, in which plasma AT111 antigen levels and 
activity are proportionately reduced, were stud- 
ied. Two polymorphic deoxyribonucleic acid 
markers were used to resolve parental AT111 al- 
leles and to trace their inheritance patterns. In 
15 of 16 cases, the structure of the affected AT111 
allele was indistinguishable from normal, sug- 
gesting that relatively small mutations, resulting 
in gene inactivation, are responsible for the 
lower ATIII levels in these affected families. In 
the remaining kindred, complete deletion of one 
AT111 allele was seen. Also investigated was the 
molecular basis for a qualitative form of AT111 
deficiency in a French-Canadian family with nor- 
mal levels of immunoreactive protein but onlv 
half the expected levels of serine protease inhibi- 
tor activity. Using polymorphic markers, the ab- 
normal allele was identified, cloned, and partially 
sequenced from the propositus. A single G + A 
transition was seen in the first base of codon 382, 
resulting in an alanine + threonine substitution 
in the defective protein. This mutation, together 
with others in this vicinity, defines a minimal 
length for a fully functional thrombin-binding 
domain. 
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The cloning and characterization of the AT111 gene 
and its complementary deoxyribonucleic acids (cDNA) 
have now made possible a detailedanalysis and a more 
comprehensive understanding of the molecular basis 
of AT111 deficiencies [7-101. Of central importance to 
this process has been the identification of restriction 
fragment length polymorphisms (RFLPs) that have 
allowed for the separation of parental alleles and for 
the ability to establish which of two alleles in affected 
persons is the mutated one. Two such RFLPs have 
been identified. One results from a silent nucleoticle 
change in exon IV of the coding region of the gene that 
either preserves or destroys a PstI restriction enzyme 
site [ 111. The second results from an insertion/deletion 
in the 5’-flanking region [121 (Figure 1). When 
genomic DNA is digested with the restriction enzyme 
PstI and subjected to Southern blotting using a full- 
length cDNA probe, these different alleles can be re- 
solved [11,13]. They have been referred to as (+) or 
(-) to connote the presence or absence of the PstI site 
in exon IV and as fast or slow to indicate the size clif- 
ferences in the 5’-flanking region PstI fragments. 
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A ntithrombin III (ATIII) deficiency can be divided into two general categories, acquired and inher- 
ited. The former results from a decrease in the syn- 
thesis of AT111 such as occurs in aclvancecl hepatic dis- 
ease. It may also result from an increased loss of 
AT111 as seen in the protein-losing enteropathies and 
nephropathies. Inherited AT111 deficiency, on the 
other hand, has a familial basis and demonstrates a 
classic menclelian mode of autosomal-dominant inheri- 
tance [l-33. Its incidence has been estimated at as low 
as 1:2,000 to 1:5,000 in the general population, al- 
though more recent studies have indicated it to be 
somewhat less common [4]. Nevertheless, it probably 
represents one of the more prevalent forms of congen- 
ital coagulopathies. 
Inherited AT111 deficiency has classically been di- 
vided into two basic types: type I, in which both anti- 
genie levels and functional activity of AT111 are pro- 
portionately reduced, and type II, in which normal or 
near-normal antigen levels are found in association 
with dysfunctional AT111 activity 121. The former type 
probably accounts for 80 to 90 percent of inherited cle- 
ficiencies and is associated with a remarkably homoge- 
neous 50 to 70 percent reduction in plasma AT111 lev- 
els in the affected persons. Type II deficiencies were 
originally discovered after observing abnormal pro- 
gressive AT111 or heparin cofactor activities despite 
what appeared to be normal plasma AT111 antigen 
levels [5,6]. We now appreciate that the type I de& 
ciencies probably result from genetic mutations that 
produce silent ATIII alleles, whereas type II defi- 
ciencies result from point mutations in the AT111 pro- 
tein that cause abnormal thrombin or heparin binding. 
NORMAL AND ABNORMAL ATM GENES 
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Figure 1. Map of the human ATIll gene. The gene is composed of seven exons (boxes, numbered I to VI) and six introns distributed over approximately 16 kb of DNA. 
Numbers above exons indrcate the amino acids encoded by that exon. Numbers -18 and -19 refer to signal peptide ammo acids. Pstl restriction sites are indicated with 
the polymorphrc Pstl site m exon IV indicated as P. The fragments generated by Pstl digestion are shown below the map. The 1.8.kb and 2.5kb fragments are invariant in 
size. The presence of the polymorphic Pstl site WIII result in the generabon of two fragments of 5.0 and 5.5 kb, whereas its absence will generate a 10.5.kb fragment. Exon 
I may contain erther a 32base parr (bp) or 108.bp m&ion in the 5’.flankmg region of the gene. The latter contams a Pstl site, and therefore exon I codmg sequences resrde 
on a 1.2kb Pstl fragment. The allele contamrng the 32.bp insert contains no Pstl site. Codmg sequences therefore reside on a 1.7.kb Pstl fragment. Enzymes whose 
recognibon sites flank these two inserhons WIII generate coding fragments differing by 76 bp. (F) = fast; (S) = slow 
Leu (BaseI) Cys (Tours;Toyama) Thr (Hamdlon) Leu (Denver) LeJ (Ubh) 
SW (Flown II) HIS (ROWI) Cys (Norlhwick Hi (Glasgow. 
Park) Shefliehl) 
HEPARIN BINDING DOMAIN TIHROMBIN BINDING WMAlN 
figure 2. Mutahons affecting ATIII acbvrbes. The normal sequence around the heparin- and thrombin-binding domains IS shown on the middle line. The amino acrds of 
the mutant proteins are indicated either above or below the normal sequence. Leu = leucine; Cys = cysteine; Thr = threonine; Pro = proline; Arg = argimne; Ala = 
alanine; Ser = serine; HIS = hishdine. 
The presence of these two frequent polymorphisms 
in the AT111 gene has permitted identification of the 
mutant alleles in nearly all affected kindreds. For ex- 
ample, in a recent collaborative study, we have been 
successful in this regard in 15 or 16 cases 1131. Our 
results can be summarized as follows: (1) all affected 
persons appear by Southern blot analysis to have two 
normal-appearing AT111 genes, so the mutations that 
cripple the affected allele do not involve large DNA 
rearrangements, insertions, or deletions; (2) in one 
case, a total deletion of one AT111 gene was observed, 
thus accounting for an apparently rare form of the de- 
ficiency state. 
It should be emphasized that the identification of 
these two polymorphisms, along with family studies, 
provides an unequivocal means of determining which 
of two normal-appearing AT111 alleles is dysfunc- 
tional. This has allowed the unambiguous cloning of 
the correct allele from genomic libraries in order to 
explore the basis for some of the type II deficiencies 
described below. 
In the simplest case, the AT111 molecule can be 
viewed as being composed of two functional domains, 
one encoding heparin binding and centered. around the 
Arg,, residue, and the other encoding the serine pro- 
tease inhibitor (thrombin-binding) domain centered 
around Arg,,,Ser,,,. A combination of classic protein 
sequencing and contemporary molecule genetic tech- 
niques has been employed to examine the basis for 
several of the known type II AT111 deficiencies. In all 
cases so far examined, single amino acid substitutions 
account for the observed effects on heparin or throm- 
bin binding. Figure 2 summarizes the mutants that 
have so far been characterized. 
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A MOLECULAR CLASSIFICATION OF ATIll 
DEFICIENCIES 
Careful correlations between AT111 antigen levels, 
functional activities, and specific mutations in the 
AT111 protein have now demonstrated that the classic 
division of inherited AT111 deficiencies into only two 
types is probably oversimplified. For example, Bock 
et a.1 1141 have sequenced the entire AT111 Utah cocl- 
ing region and have shown that the only mutation is 
one that alters the normal Pro.l,,T to Leu 1141. Yet, per- 
sons with this mutation have consistently low AT111 
levels [15]. This is clearly not a classic type II clefi- 
ciency in which antigen levels are unaffected. Rather, 
either the single nucleoticle substitution reduces the 
rate of messenger ribonucleic acid transcription or 
translation, or the mutant protein has a reduced 
plasma half-life. We have proposed a more refined 
classification scheme that takes into account these clif- 
ferences and that can be correlated with specific 
AT111 mutations (Table I) [lG]. We suggest that 
type I deficiencies arise as a result of what is probably 
a heterogeneous group of disorders not unlike those 
causing the beta-thalassemias. These would include 
frame shift and nonsense mutations as well as those 
affecting splice junctions, promoters, and enhancers 
in and around the actual structural gene. In rare 
cases, larger deletions or rearrangements might ac- 
count for the loss of gene function. Unlinked muta- 
tions might affect genes whose products are con- 
cerned with maintaining normal AT111 messenger ri- 
bonucleic acid or protein levels, although such muta- 
tions have not been described. 
l)pe II deficiencies are of a qualitative nature in 
which AT111 levels and heparin binding are within the 
normal range but thrombin binding is defective. 
ATIIIs Denver and Hamilton are examples [17,18]. 
Other variants of this type include ATIIIs Northwick 
Park, Trenton, and Milan0 (Figure 2) [19]. 
Type IIIA deficiencies alter the heparin-binding 
domain and result in diminished cofactor activity 
while leaving progressive AT111 activity unaffected. 
ATIIIs Toyama, Tours, and Rouen I and II are within 
this group [20X3]. 
Type IIIB deficiencies also affect the heparin-bincl- 
ing domain but actually result in increased heparin 
binding. This has been described for AT111 Chicago, 
although the exact molecular defect has not been elu- 
cidated. 
Type IV deficiencies are exemplified by AT111 
Utah, where a single mutation accounts for a recluc- 
tion in antigen level as well as for reduced thrombin- 
binding capacity [ 141. 
Class V deficiencies are similar in nature to type 
IVs in that quantitative ancl qualitative defects exist 
simultaneously. However, in this class, heparin-bind- 
ing activity is reduced, whereas thrombin binding is 
normal. ATIIIs Base1 and Roma are cases in point 
124,251, although in the latter case, the exact molecu- 
lar defect has not been determined. 
CONCLUSIONS AND PROSPECTS FOR THE FUTURE 
Clearly, the past five years have seen remarkable 
progress in our understanding of inherited AT111 defi- 
ciency. Particularly useful has been the cataloging of 
the individual point mutations that contribute to the 
various qualitative disorders illustratecl in Figure 2, 
TABLE I 
Classification of inherited ATIll Deficiencies 
Antigen Heparin lhrombin 
Type Level Binding Binding Examples 
I I I I All dehctencles asocIaled wlh 
structurally normal ATIII molecules 
II 
ii: 
NL 1 Denver, HamIlton 
IIIA I Toyama, Tours, Rouen 






11 Rome, Base1 
I. 1 = decreased: t = Increased; NL = normal levels. 
*In class IV mutabons. antigen levels and hepann bindmg are reduced ptoportionalty. 
Thrombrn brndmg IS reduced even more, owrng to an alteration of the binding sue. Thrs 
feature drshngurshes thus class from the type I mutations In whtch antigen levels, hepann 
brndmg and ihrombm bmdrng are all reduced proportronally. 
Tin class V mutations, anbgen levels and thrombm bmding are reduced proportionately. 
Hepann bmdrnn IS reduced even further, presumably because of a pomt mutahon rn or 
near the N-termmal hepann-bmdmg domam. 
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as they now allow us to estimate the minimal func- 
tional sizes of the heparin- and thrombin-binding clo- 
mains. It can be predicted that new techniques such as 
the polymerase chain reaction 1261 and direct genomic 
sequencing will enable workers to quickly and easily 
compile many additional naturally occurring mutants 
without resorting to long and laborious protein se- 
quencing or molecular cloning techniques. High-effi- 
ciency oligonucleoticle-directed mutagenesis [27] cou- 
pled with in. uitro and/or i?z uivo expression [28] will 
permit the generation of multiple individual point 
mutations and determination as to how they affect 
various aspects of AT111 structure and function. On 
the clinical front, it might be expected that similar 
approaches will allow the production of recombinant 
AT111 molecules with extended i?z viva half-lives that 
might serve as a form of second-generation replace- 
ment therapy in persons at high risk for the complica- 
tions associated with inherited AT111 deficiency. 
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